Access and Evidence
How automation is changing regulatory affairs
Post pandemic, pharma and regulators are both working to accelerate the transformative power of electronic filing
More Access and Evidence Articles
Access and Evidence
An early peek at the FDA’s RWE ‘cookbook’
The FDA is developing guidelines that will help pharma accelerate its adoption of RWE, this is what the industry should know
Access and Evidence
The future is bright for RWE in pharma approvals
The FDA and other regulatory bodies are increasingly willing to accept real-world evidence as part of approvals. Pharma is up to the task
Access and Evidence
Payers and the ABCs of digital literacy
Convincing payers of the value of digital add-ons and of drug/device combinations requires pharma to demonstrate that patients and other stakeholders understand how to use them
Access and Evidence
Decoding the patient journey with RWD
Patient real-world data contains a wealth of potentially valuable information for life sciences commercial teams, if they can filter out the noise
Access and Evidence
Keeping it real: How data is driving healthcare reform in China
China’s healthcare market is ripe for those capable of helping it capture the vast potential of real-world data
Access and Evidence
Including the caregiver in access submissions
Partnering with caregivers can help build a more powerful case for re-imbursement if pharma can gather the right evidence
Access and Evidence
Bringing innovation to rare disease patients in Europe
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Access and Evidence
Survey results: Accelerating digital transformation during COVID-19
View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations